Magnetically Responsive Nanoplatform Targeting CircRNA Circ_0058051 Inhibits Hepatocellular Carcinoma Progression

Overview

Journal Drug Deliv Transl Res

Publisher Springer

Specialty Pharmacology

Date 2022 Sep 16

PMID 36114310

Authors

Song You

Zijin Luo

Niangmei Cheng

Ming Wu

Yongping Lai

Fei Wang

Xiaoyuan Zheng

Yingchao Wang

Xiaolong Liu

Jingfeng Liu

Bixing Zhao

Affiliations

Soon will be listed here.

Abstract

Circular RNAs (circRNAs) are a class of highly stable and closed-loop noncoding RNA that are involved in the occurrence and development of hepatocellular carcinoma (HCC). However, little is known about the therapeutic role of circRNAs in HCC. We found that high circ_0058051 expression was negatively correlated with the prognosis of HCC patients. Circ_0058051 knockdown attenuated the proliferation and colony formation, meanwhile inhibited migration of HCC cells. Circ_0058051 may be used as a target for HCC gene therapy. We synthesized a novel small interfering RNA (siRNA) delivery system, PEG-PCL-PEI-C14-SPIONs (PPPCSs), based on superparamagnetic iron oxide nanoparticles (SPIONs). PPPCSs protected the siRNA of circ_0058051 from degradation in serum and effectively delivered siRNA into SMMC-7721 cells. Meanwhile, intravenous injection of the PPPCSs/siRNA complex could inhibit tumor growth in the subcutaneous tumor model. In addition, the nanocomposite is not toxic to the organs of nude mice. The above results show that PPPCSs/si-circ_0058051 complex may provide a novel and promising method of HCC treatment.

Citing Articles

Nanoparticles-Delivered Circular RNA Strategy as a Novel Antitumor Approach.

Racca L, Liuzzi E, Comparato S, Giordano G, Pignochino Y Int J Mol Sci. 2024; 25(16).

PMID: 39201617 PMC: 11354327. DOI: 10.3390/ijms25168934.

Circ-IP6K2 suppresses tumor progression by modulating the miR-1292-5p/CAMK2N1 signal in clear cell renal cell carcinoma.

Tang J, Yang L, Wu Q, Yang Y, Su Y, Chen Y Funct Integr Genomics. 2024; 24(4):122.

PMID: 38980439 DOI: 10.1007/s10142-024-01398-9.

Role of circular RNAs and gut microbiome in gastrointestinal cancers and therapeutic targets.

Abdullah S, Abdullah S, Hussen B, Younis Y, Rasul M, Taheri M Noncoding RNA Res. 2024; 9(1):236-252.

PMID: 38192436 PMC: 10771991. DOI: 10.1016/j.ncrna.2023.12.002.

Hepatocellular Carcinoma: Up-regulated Circular RNAs Which Mediate Efficacy in Preclinical Models.

Weidle U, Nopora A Cancer Genomics Proteomics. 2023; 20(6):500-521.

PMID: 37889063 PMC: 10614070. DOI: 10.21873/cgp.20401.

Exosomal circRNA: emerging insights into cancer progression and clinical application potential.

Zhang F, Jiang J, Qian H, Yan Y, Xu W J Hematol Oncol. 2023; 16(1):67.

PMID: 37365670 PMC: 10294326. DOI: 10.1186/s13045-023-01452-2.

References

Pongrac I, Pavicic I, Milic M, Brkic Ahmed L, Babic M, Horak D . Oxidative stress response in neural stem cells exposed to different superparamagnetic iron oxide nanoparticles. Int J Nanomedicine. 2016; 11:1701-15. PMC: 4853020. DOI: 10.2147/IJN.S102730. View

Maier-Hauff K, Ulrich F, Nestler D, Niehoff H, Wust P, Thiesen B . Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme. J Neurooncol. 2010; 103(2):317-24. PMC: 3097345. DOI: 10.1007/s11060-010-0389-0. View

Dulinska-Litewka J, Lazarczyk A, Halubiec P, Szafranski O, Karnas K, Karewicz A . Superparamagnetic Iron Oxide Nanoparticles-Current and Prospective Medical Applications. Materials (Basel). 2019; 12(4). PMC: 6416629. DOI: 10.3390/ma12040617. View

Liu J, Zhang Y, Zeng Q, Zeng H, Liu X, Wu P . Delivery of RIPK4 small interfering RNA for bladder cancer therapy using natural halloysite nanotubes. Sci Adv. 2019; 5(9):eaaw6499. PMC: 6760933. DOI: 10.1126/sciadv.aaw6499. View

Gavrilov K, Saltzman W . Therapeutic siRNA: principles, challenges, and strategies. Yale J Biol Med. 2012; 85(2):187-200. PMC: 3375670. View

Patop I, Kadener S . circRNAs in Cancer. Curr Opin Genet Dev. 2017; 48:121-127. PMC: 5877416. DOI: 10.1016/j.gde.2017.11.007. View

Sorasitthiyanukarn F, Muangnoi C, Thaweesest W, Ratnatilaka Na Bhuket P, Jantaratana P, Rojsitthisak P . Polyethylene Glycol-Chitosan Oligosaccharide-Coated Superparamagnetic Iron Oxide Nanoparticles: A Novel Drug Delivery System for Curcumin Diglutaric Acid. Biomolecules. 2020; 10(1). PMC: 7023009. DOI: 10.3390/biom10010073. View

Yu J, Xu Q, Wang Z, Yang Y, Zhang L, Ma J . Circular RNA cSMARCA5 inhibits growth and metastasis in hepatocellular carcinoma. J Hepatol. 2018; 68(6):1214-1227. DOI: 10.1016/j.jhep.2018.01.012. View

Ding B, Fan W, Lou W . hsa_circ_0001955 Enhances Proliferation, Migration, and Invasion of HCC Cells through miR-145-5p/NRAS Axis. Mol Ther Nucleic Acids. 2020; 22:445-455. PMC: 7554323. DOI: 10.1016/j.omtn.2020.09.007. View

10.

Scott L . Givosiran: First Approval. Drugs. 2020; 80(3):335-339. DOI: 10.1007/s40265-020-01269-0. View

11.

Javanbakht H, Mueller H, Walther J, Zhou X, Lopez A, Pattupara T . Liver-Targeted Anti-HBV Single-Stranded Oligonucleotides with Locked Nucleic Acid Potently Reduce HBV Gene Expression In Vivo. Mol Ther Nucleic Acids. 2018; 11:441-454. PMC: 5992345. DOI: 10.1016/j.omtn.2018.02.005. View

12.

Ray K, Wright R, Kallend D, Koenig W, Leiter L, Raal F . Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. N Engl J Med. 2020; 382(16):1507-1519. DOI: 10.1056/NEJMoa1912387. View

13.

Sims C, Hanna S, Heller D, Horoszko C, Johnson M, Montoro Bustos A . Redox-active nanomaterials for nanomedicine applications. Nanoscale. 2017; 9(40):15226-15251. PMC: 5648636. DOI: 10.1039/c7nr05429g. View

14.

Hoy S . Patisiran: First Global Approval. Drugs. 2018; 78(15):1625-1631. DOI: 10.1007/s40265-018-0983-6. View

15.

Asadi N, Annabi N, Mostafavi E, Anzabi M, Khalilov R, Saghfi S . Synthesis, characterization and in vitro evaluation of magnetic nanoparticles modified with PCL-PEG-PCL for controlled delivery of 5FU. Artif Cells Nanomed Biotechnol. 2018; 46(sup1):938-945. DOI: 10.1080/21691401.2018.1439839. View

16.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

17.

Huang X, Zhang P, Wei C, Peng R, Lu J, Gao C . Circular RNA circMET drives immunosuppression and anti-PD1 therapy resistance in hepatocellular carcinoma via the miR-30-5p/snail/DPP4 axis. Mol Cancer. 2020; 19(1):92. PMC: 7236145. DOI: 10.1186/s12943-020-01213-6. View

18.

Qiyami Hour F, Moghadam A, Shakeri-Zadeh A, Bakhtiyari M, Shabani R, Mehdizadeh M . Magnetic targeted delivery of the SPIONs-labeled mesenchymal stem cells derived from human Wharton's jelly in Alzheimer's rat models. J Control Release. 2020; 321:430-441. DOI: 10.1016/j.jconrel.2020.02.035. View

19.

Xu J, Ji L, Liang Y, Wan Z, Zheng W, Song X . CircRNA-SORE mediates sorafenib resistance in hepatocellular carcinoma by stabilizing YBX1. Signal Transduct Target Ther. 2020; 5(1):298. PMC: 7762756. DOI: 10.1038/s41392-020-00375-5. View

20.

Barve M, Wang Z, Kumar P, Jay C, Luo X, Bedell C . Phase 1 Trial of Bi-shRNA STMN1 BIV in Refractory Cancer. Mol Ther. 2015; 23(6):1123-1130. PMC: 4817753. DOI: 10.1038/mt.2015.14. View